Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 22, 2025BMC CancerOpen Access

Evaluating the safety and feasibility of prophylactic third-party NK cell administration in high-risk AML patients post-HSCT

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMaryam BarkhordarSTShima TavoosiSTShirin Tavakoli

Discussion

Loading...

Member takes

Overview

Trial shows prophylactic NK cell infusions are safe, yet relapse in AML patients suggests further studies needed.

Key Points

  • This study aims to evaluate the safety and feasibility of prophylactic NK cell administration in high-risk AML patients after HSCT.
  • Single-arm, non-randomized trial design
  • 11 high-risk AML patients received 2 doses of NK cells (5 x 10⁶ cells/kg)
  • Endpoints included safety, relapse incidence, overall survival, and disease-free survival
  • NK cell infusion was well tolerated with no grade 3 or higher toxicities
  • Acute graft-versus-host disease occurred in 36.4% of patients
  • 27.3% relapse rate at median 256-day follow-up

Cite This Study

Barkhordar et al. (2025) studied this question.

synapsesocial.com/papers/6924e3ddc0ce034ddc34e981https://doi.org/10.1186/s12885-025-15362-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1NK cell adoptive transfer in acute myeloid leukemia: a systematic review and meta-analysis2026
  2. 2Results of a phase I trial with Haploidentical <scp>mbIL</scp>‐21 ex vivo expanded <scp>NK</scp> cells for patients with multiply relapsed and refractory <scp>AML</scp>2024 · 35 citations
  3. 3A systematic review of the last two decades of NK cell-based clinical trials: state of the art of AML therapy2025 · 4 citations
  4. 4Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial2024 · 15 citations
  5. 5The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation2024 · 25 citations